Intercept Pharma (ICPT): Symphony Health Indicates Above Consensus Ocaliva Sales - Wedbush
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) and sees growing Ocaliva sales and multiple catalysts in the next 6-18 months.
Symphony Health (SH) estimated just over $5 million for Q3 OCA sales— above consensus of $3.5 million. Based on the monthly estimates for OCA sales for PBC, the analyst estimates Q3 OCA sales of at least $5 million, ahead of the Thomson consensus of ~$3.5 million (range $1.6 million to $7.2 million).
There is no change to estimates at this time since Ocaliva was only launched in June and there is not a consistent capture rate for the Symphony Health monthly estimates compared with reported sales.
No change to the price target of $239.
Shares of Intercept Pharmaceuticals closed at $154.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Downgrades PennTex Midstream Partners, LP (PTXP) to Hold
- Intercept Pharma (ICPT) on Watch as Genfit Said to Explore Options Including Sale
- UPDATE: Stifel Upgrades Martin Midstream Partners (MMLP) to Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesLiana Moussatos
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!